ReviewDiscover oncology2025
Ki-67 and 21-gene recurrence score assay in decision making for adjuvant chemotherapy in breast cancer patients.
Review in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Development and validation of an interpretable model based on ultrasound radiomics for predicting Ki-67 expression levels in breast cancer.Translational cancer research · 2026Article
- Evaluating the Association of Ki-67 with Oncotype DX Recurrence Score in Early-Stage ER-Positive/HER2-Negative Breast Cancer.Cancers · 2026Article
- The Prognostic Impact of the Ki-67 Proliferation Index in Patients with Surgically Treated Spinal Metastases.Cancers · 2026Article
- Multifunctional chitosan-doxorubicin nanocarriers: advancing targeted breast cancer chemotherapy.Molecular cancer · 2026Review
- Optimizing endocrine adjuvant therapy in HR+/HER2- breast cancer: supplemental strategies and innovations.Annals of medicine and surgery (2012) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although significant advances have been made in the molecular subtyping of breast cancers, identification of patients who do not benefit from the chemotherapy is a major challenge. Pioneer studies have examined the predictive value of the clinicopathological factors, such as tumor size, disease stage, the expression levels of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER2) molecules and more importantly tumor cells proliferation index (Ki-67) to help guide patients' treatment and predict their outcome in the adjuvant chemotherapy setting. However, despite their clinical importance, no consensus is reached on their validity for chemotherapy decision. These challenges have ignited researchers to evaluate genomic signatures, which has led to the introduction of several genomic tests that can now help oncologists to include/exclude chemotherapy from the treatment regimen with more confidence. The present review aims to look back over the literature on the clinical significance of Ki-67 as well as the 21-gene recurrence score assay in identification of breast cancer patients who may benefit from the adjuvant chemotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.